pharmaceutical industry

Indian pharmaceutical giant Sun Pharma is set to acquire US-based Organon & Co. for $11.75 billion in an all-cash deal. This landmark acquisition, one of India's largest overseas ventures, will propel Sun Pharma into the top 25 global pharma companies. The move significantly bolsters its presence in women's health and biosimilars, expanding its global reach across 150 countries.

Indian companies are significantly boosting the US economy with substantial investments, creating thousands of jobs, and driving innovation. Senior officials highlighted nearly $16.4 billion in cumulative FDI, supporting over 70,000 jobs and significant R&D. Further commitments are anticipated, underscoring India's growing role in key American sectors.

Odisha Chief Minister Mohan Charan Majhi is embarking on a four-city Gujarat tour to woo investors. The visit, starting Tuesday, will feature a roadshow in Ahmedabad and discussions focused on key sectors like chemicals, metals, and pharmaceuticals.

India remains on the US Trade Representative's Priority Watch List for intellectual property protection, a designation that carries no legal ramifications but serves as a negotiation tool. The US cited concerns over pharmaceutical IP rules, while India maintains its regime ensures affordable medicine access and WTO compliance.

India's trade deficit with China has surged to $112.1 billion, driven by a deep reliance on Chinese industrial supplies. Manufacturing sectors like electronics and pharmaceuticals depend heavily on Chinese components, creating significant supply chain risks. Experts urge India to boost domestic production and diversify sourcing to mitigate these vulnerabilities.

Sun Pharmaceutical Industries Ltd has agreed to acquire US-based Organon & Co for $11.75 billion in an all-cash deal. This significant outbound acquisition is expected to close in early 2027, strengthening Sun Pharma's global presence in women's health and biosimilars.

India is strategically balancing its trade with China, aiming to boost domestic manufacturing and exports while reducing reliance on Chinese inputs. The nation is building resilient supply chains and increasing its export capacity, though a complete decoupling remains unfeasible. Efforts are underway to diversify sourcing and address the widening trade deficit.